On November 19, Twist Bioscience Corp rose 4.31% in Pre-Market Trading, trading at $121.3652 per share, with turnover of $240,500.
The move came as the market continued to digest the company’s latest earnings and management’s outlook for slower AI drug discovery growth, while analyst target revisions remained divided.
Background context shows Twist Bioscience Corp reported fiscal fourth-quarter revenue of $126.6 million and a loss of $0.32 per share, both better than consensus, while fiscal first-quarter revenue guidance of $130 million to $132 million and full-year revenue guidance of $550 million to $560 million were also slightly above expectations. Even so, management indicated slower growth in AI drug discovery-related business, prompting UBS to cut its target price to $120, Jefferies to lower its target to $125, and Guggenheim to reduce its target to $150, while Piper Sandler raised its target to $140, underscoring a split in analyst views.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments